Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D03PUA
|
|||
Drug Name |
Siltuximab
|
|||
Synonyms |
Sylvant (TN); Siltuximab (USAN/INN); D09669; 541502-14-1
Click to Show/Hide
|
|||
Drug Type |
Monoclonal antibody
|
|||
Indication | Idiopathic multicentric Castlemans disease [ICD-11: 2A81.Y] | Approved | [1] | |
Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 3 | [2] | ||
Therapeutic Class |
Antiviral Agents
|
|||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | HUMAN interleukin 6 (IL6) | Target Info | Inhibitor | [3], [4] |
References | Top | |||
---|---|---|---|---|
REF 1 | FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (BLA) 125496. | |||
REF 2 | ClinicalTrials.gov (NCT04330638) Treatment of COVID-19 Patients With Anti-interleukin Drugs. U.S. National Institutes of Health. | |||
REF 3 | Siltuximab. In: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006. 2018 Dec 3. | |||
REF 4 | Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS) J Autoimmun. 2020 Apr 10:102452. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.